The prevalence of cancer-associated autoantibodies in patients with gastric cancer and progressive grades of premalignant lesions

Irēna Meistere, Simone Werner, Pawel Zayakin, Karīna Siliņa, Undīne Rulle, Angelina Pismennaja, Daiga Šantare, Ilze Kikuste, Sergejs Isajevs, Marcis Leja, Limas Kupčinskas, Juozas Kupčinskas, Laimas Jonaitis, Chun Ying Wu, Hermann Brenner, Aija Linē, Zane Kalniņa*

*此作品的通信作者

研究成果: Article同行評審

23 引文 斯高帕斯(Scopus)

摘要

Background: Serum autoantibodies against tumor-associated antigens (TAAs) are detectable in early-stage gastric cancer patients; however, the time point during cancerogenesis when they appear in circulation is still obscure. Methods: In this study, we developed a recombinant antigen microarray and analyzed the prevalence of autoantibodies against 102 TAAs in 829 gastric cancer patients and 929 healthy controls from Caucasian and Asian populations, as well as 100 patients with chronic atrophic gastritis and 775 individuals staged according to different grades of intestinal metaplasia. Results: Six antigens, including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53, and MAGEA3, were predominantly reacting with sera from gastric cancer patients when compared with healthy controls, and the seroreactivity was associated with intestinal-type gastric cancer, but not with patients' Helicobacter pylori status, grade, age, gender, or stage of gastric cancer. We detected gastric cancer–associated seroreactivity in 13% of patients with advanced/severe intestinal metaplasia, which was increased in comparison with mild/moderate intestinal metaplasia (5.3%) and was comparable with that seen in early-stage gastric cancer patients (12%). Moreover, by testing serum samples taken 1 to 9 years before the clinical diagnosis of 18 incident gastric cancer cases, we detected autoantibody responses against several TAAs—SOX2, MYC, BIRC5, IGF2BP1, and MUC1. Conclusions: Our results suggest that humoral immune response against TAAs is generated already during premalignant stages. Impact: Based on the obtained results, cancer-associated autoantibodies might make a valuable contribution to the stratification of high-risk patients with premalignant lesions in the stomach through enhancing the positive predictive power of existing risk models.

原文English
頁(從 - 到)1564-1574
頁數11
期刊Cancer Epidemiology Biomarkers and Prevention
26
發行號10
DOIs
出版狀態Published - 1 10月 2017

指紋

深入研究「The prevalence of cancer-associated autoantibodies in patients with gastric cancer and progressive grades of premalignant lesions」主題。共同形成了獨特的指紋。

引用此